Mutation of the Proline P81 into a Serine Modifies the Tumour Suppressor Function of the Von Hippel-Lindau Gene in the CcRCC

Overview

Journal Br J Cancer

Specialty Oncology

Date 2022 Sep 29

PMID 36175619

Authors

Franck Chesnel

Emmanuelle Jullion

Olivier Delalande

Anne Couturier

Adrien Alusse

Xavier Le Goff

Marion Lenglet

Betty Gardie

Caroline Abadie

Yannick Arlot-Bonnemains

Affiliations

Soon will be listed here.

Abstract

Background: The von Hippel-Lindau disease is an autosomal dominant syndrome associated with tumour formation in various tissues, such as retina, central nervous system, kidney, and adrenal glands. VHL gene deletion or mutations support the development of various cancers. Unclassified VHL variants also referred as "of unknown significance" result from gene mutations that have an unknown or unclear effect on protein functions. The P81S mutation has been linked to low penetrance Type 1 disease but its pathogenic function was not clearly determined.

Methods: We established a stable cell line expressing the pVHL (c.241C>T, P81S) mutant. Using biochemical and physiological approaches, we herein analysed pVHL folding, stability and function in the context of this VHL single missense mutation.

Results: The P81S mutation mostly affects the non-canonical function of the pVHL protein. The cells expressing the pVHLP81S acquire invasive properties in relation with modified architecture network.

Conclusion: We demonstrated the pathogenic role of this mutation in tumour development in vhl patients and confirm a medical follow up of family carrying the c.241C>T, P81S.

References

Lewis M, Roberts B . Role of the C-terminal alpha-helical domain of the von Hippel-Lindau protein in its E3 ubiquitin ligase activity. Oncogene. 2003; 23(13):2315-23. DOI: 10.1038/sj.onc.1207384. View

Maranchie J, Vasselli J, Riss J, Bonifacino J, Linehan W, Klausner R . The contribution of VHL substrate binding and HIF1-alpha to the phenotype of VHL loss in renal cell carcinoma. Cancer Cell. 2002; 1(3):247-55. DOI: 10.1016/s1535-6108(02)00044-2. View

Nordstrom-OBrien M, van der Luijt R, van Rooijen E, van den Ouweland A, Majoor-Krakauer D, Lolkema M . Genetic analysis of von Hippel-Lindau disease. Hum Mutat. 2010; 31(5):521-37. DOI: 10.1002/humu.21219. View

Zbar B, Kishida T, Chen F, Schmidt L, Maher E, Richards F . Germline mutations in the Von Hippel-Lindau disease (VHL) gene in families from North America, Europe, and Japan. Hum Mutat. 1996; 8(4):348-57. DOI: 10.1002/(SICI)1098-1004(1996)8:4<348::AID-HUMU8>3.0.CO;2-3. View

Lenglet M, Robriquet F, Schwarz K, Camps C, Couturier A, Hoogewijs D . Identification of a new exon and complex splicing alterations in familial erythrocytosis or von Hippel-Lindau disease. Blood. 2018; 132(5):469-483. DOI: 10.1182/blood-2018-03-838235. View

Leonardi E, Murgia A, Tosatto S . Adding structural information to the von Hippel-Lindau (VHL) tumor suppressor interaction network. FEBS Lett. 2009; 583(22):3704-10. DOI: 10.1016/j.febslet.2009.10.070. View

Minervini G, Quaglia F, Tabaro F, Tosatto S . Genotype-phenotype relations of the von Hippel-Lindau tumor suppressor inferred from a large-scale analysis of disease mutations and interactors. PLoS Comput Biol. 2019; 15(4):e1006478. PMC: 6464237. DOI: 10.1371/journal.pcbi.1006478. View

Ivan M, Kaelin Jr W . The von Hippel-Lindau tumor suppressor protein. Curr Opin Genet Dev. 2001; 11(1):27-34. DOI: 10.1016/s0959-437x(00)00152-0. View

Hes F, McKee S, Taphoorn M, Rehal P, van der Luijt R, McMahon R . Cryptic von Hippel-Lindau disease: germline mutations in patients with haemangioblastoma only. J Med Genet. 2000; 37(12):939-43. PMC: 1734505. DOI: 10.1136/jmg.37.12.939. View

10.

Knauth K, Cartwright E, Freund S, Bycroft M, Buchberger A . VHL mutations linked to type 2C von Hippel-Lindau disease cause extensive structural perturbations in pVHL. J Biol Chem. 2009; 284(16):10514-22. PMC: 2667738. DOI: 10.1074/jbc.M809056200. View

11.

Desimone M, Rathmell W, Threadgill D . Pleiotropic effects of the trichloroethylene-associated P81S VHL mutation on metabolism, apoptosis, and ATM-mediated DNA damage response. J Natl Cancer Inst. 2013; 105(18):1355-64. PMC: 3776265. DOI: 10.1093/jnci/djt226. View

12.

Weirich G, Klein B, Wohl T, Engelhardt D, Brauch H . VHL2C phenotype in a German von Hippel-Lindau family with concurrent VHL germline mutations P81S and L188V. J Clin Endocrinol Metab. 2002; 87(11):5241-6. DOI: 10.1210/jc.2002-020651. View

13.

Hascoet P, Chesnel F, Jouan F, Le Goff C, Couturier A, Darrigrand E . The pVHL isoform is not a tumor suppressor and up-regulates a subset of pro-tumorigenic genes including and . Oncotarget. 2017; 8(44):75989-76002. PMC: 5652680. DOI: 10.18632/oncotarget.18376. View

14.

Chesnel F, Hascoet P, Gagne J, Couturier A, Jouan F, Poirier G . The von Hippel-Lindau tumour suppressor gene: uncovering the expression of the pVHL172 isoform. Br J Cancer. 2015; 113(2):336-44. PMC: 4506380. DOI: 10.1038/bjc.2015.189. View

15.

Gordan J, Simon M . Hypoxia-inducible factors: central regulators of the tumor phenotype. Curr Opin Genet Dev. 2007; 17(1):71-7. PMC: 3215290. DOI: 10.1016/j.gde.2006.12.006. View

16.

Gallou C, Chauveau D, Richard S, Joly D, Giraud S, Olschwang S . Genotype-phenotype correlation in von Hippel-Lindau families with renal lesions. Hum Mutat. 2004; 24(3):215-24. DOI: 10.1002/humu.20082. View

17.

Gnarra J, Tory K, Weng Y, Schmidt L, Wei M, Li H . Mutations of the VHL tumour suppressor gene in renal carcinoma. Nat Genet. 1994; 7(1):85-90. DOI: 10.1038/ng0594-85. View

18.

Brauch H, Weirich G, Klein B, Rabstein S, Bolt H, Bruning T . VHL mutations in renal cell cancer: does occupational exposure to trichloroethylene make a difference?. Toxicol Lett. 2004; 151(1):301-10. DOI: 10.1016/j.toxlet.2003.12.074. View

19.

STEBBINS C, Kaelin Jr W, Pavletich N . Structure of the VHL-ElonginC-ElonginB complex: implications for VHL tumor suppressor function. Science. 1999; 284(5413):455-61. DOI: 10.1126/science.284.5413.455. View

20.

Nguyen H, Yang H, Fribourgh J, Wolfe L, Xiong Y . Insights into Cullin-RING E3 ubiquitin ligase recruitment: structure of the VHL-EloBC-Cul2 complex. Structure. 2015; 23(3):441-449. PMC: 4351159. DOI: 10.1016/j.str.2014.12.014. View